Announcement

Collapse
No announcement yet.

ECDC- Updated rapid risk assessment on Zika virus in the Americas and potential complications

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • ECDC- Updated rapid risk assessment on Zika virus in the Americas and potential complications


    22 Jan 2016

    ​The Zika virus epidemic continues to spread in the Americas. Since the last ECDC rapid risk assessment published on 10 December 2015, 13 additional countries or territories have reported laboratory confirmed autochthonous transmission. Further information is now available on the number of babies born with microcephaly in Brazil and several Zika-affected countries have reported unusual increases in Guillain–Barr? syndrome. ECDC has updated its assessment and options for mitigation in its new rapid risk assessment.

    The risk assessment concludes that despite growing evidence of a link between intra-uterine Zika virus infection and adverse pregnancy outcomes, a causal link between these events has not yet been confirmed. It also concludes that further epidemiological studies are required to assess the strength of the association between Guillain–Barr? syndrome and Zika virus infection. No new scientific evidence about the association of Guillain-Barr? and Zika virus infection has been published.

    As of 19 January 2016, autochthonous cases of Zika virus infection were reported from 23 countries or territories worldwide within the past two months and 27 countries or territories have reported autochthonous cases within the past nine months.

    The findings from investigations of an additional four suspected cases of microcephaly with a possible association to Zika virus infection were reported by the Brazilian authorities. In addition, a recent journal publication mentions six additional cases but with no further details. The Hawaii (USA) Department of Health announced a laboratory confirmed case of Zika virus infection in a baby born with microcephaly from a mother who was pregnant when she resided in Brazil in May 2015.

    Two new countries, El Salvador and Venezuela, have reported an unusual increase above the baseline of Guillain-Barr? syndrome, concomitant with the development of Zika outbreaks in the country. This observation supports a temporal and spatial association as that seen in French Polynesia.
    Options for mitigation


    The main options for mitigation that public health authorities in EU/EEA Member States should consider include the following (see the rapid risk assessment for the full description of the options):

    Surveillance
    • Increase awareness of clinicians and travel health clinics so Zika virus infection is considered in their differential diagnosis.
    • Enhance vigilance towards the early detection of imported cases.
    • Strengthen laboratory capacity.
    • Increase awareness among obstetricians, paediatricians and neurologists that Zika virus infections should be investigated for patients presenting with congenital central nervous system malformations, microcephaly and Guillain–Barr? syndrome.
    Safety of substances of human origin
    • Blood safety authorities should consider the deferral of donors with a relevant travel history to affected areas, in line with measures defined for dengue virus.
    Information to travellers and EU residents in affected areas

    Recent trends can be used to describe the affected countries as either:
    • Experiencing a rapidly evolving Zika virus epidemic with an increasing or widespread transmission; or
    • Reporting sporadic transmission following recent introduction.
    The following options should be considered by public health authorities:
    • Advise all travellers to affected areas to take protective measures to prevent mosquito bites, including during the day.
    • Advise travellers with immune disorders or severe chronic illnesses to seek medical advice before travelling.
    • Advise pregnant women and women who are trying to become pregnant, to discuss travel plans with their healthcare providers and to consider postponing their travel to affected areas, especially to areas with increasing or widespread transmission.
    • Advise EU citizens who live in affected areas to take protective measures to prevent mosquito bites, particularly pregnant women and women who are trying to become pregnant living in areas with increasing or widespread transmission.
    • Travellers showing symptoms compatible with dengue, chikungunya or Zika virus disease within three weeks after returning from an affected area should contact their healthcare provider.
    • Pregnant women who have travelled to areas with Zika virus transmission should mention their travel during antenatal visits in order to be assessed and monitored appropriately.
    Read the Rapid Risk Assessment:

    Zika virus disease epidemic: potential association with microcephaly and Guillain-Barr? syndrome (first update)


    More information

    Zika virus infection: Health topic page
    Zika virus infection: Countries reporting local transmission of confirmed Zika virus infections in past nine months
    Zika virus infection: Epidemiological updates
    Zika virus infection: Factsheet for health professionals



    Rapid Risk assessments on Zika:Rapid Risk assessments on Zika:

    Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barr? syndrome, 10 December 2015
    Microcephaly in Brazil potentially linked to the Zika virus epidemic, 24 November 2015
    Zika virus infection outbreak, Brazil and the Pacific region, 26 May 2015

    Zika virus infection outbreak, French Polynesia, 14 February 2015






    ?Addressing chronic disease is an issue of human rights ? that must be our call to arms"
    Richard Horton, Editor-in-Chief The Lancet

    ~~~~ Twitter:@GertvanderHoek ~~~ GertvanderHoek@gmail.com ~~~

  • #2
    Originally posted by Gert van der Hoek View Post


    Safety of substances of human origin

    Blood safety authorities should consider the deferral of donors with a relevant travel history to affected areas, in line with measures defined for dengue virus.


    Eurosurveillance, Volume 19, Issue 14, 10 April 2014
    Rapid communications

    POTENTIAL FOR ZIKA VIRUS TRANSMISSION THROUGH BLOOD TRANSFUSION DEMONSTRATED DURING AN OUTBREAK IN FRENCH POLYNESIA, NOVEMBER 2013 TO FEBRUARY 2014
    ...
    We detected an unexpectedly high number of positive asymptomatic blood donors (42/1,505; 3%). To date, no post-transfusion ZIKAV infection has been reported in recipients of ZIKAV-positive blood in French Polynesia; however, haemovigilance studies are still ongoing.
    ...

    Since October 2013, French Polynesia has experienced the largest documented outbreak of Zika virus (ZIKAV) infection. To prevent transmission of ZIKAV by blood transfusion, specific nucleic acid testing of blood donors was implemented. From November 2013 to February 2014: 42 (3%) of 1,505 blood donors, although asymptomatic at the time of blood donation, were found positive for ZIKAV by PCR. Our results serve to alert blood safety authorities about the risk of post-transfusion Zika fever.
    "Safety and security don't just happen, they are the result of collective consensus and public investment. We owe our children, the most vulnerable citizens in our society, a life free of violence and fear."
    -Nelson Mandela

    Comment

    Working...
    X